Critical need for pharmacologic treatment options in NAFLD: A pediatric perspective

Nonalcoholic fatty liver disease (NAFLD) affects up to 70% of children with obesity and has become the number one etiology for liver transplant in the United States. Early, effective intervention is critical to prevent disease progression into adulthood. Yet, it is seldom achieved through lifestyle...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and translational science 2021-05, Vol.14 (3), p.781-783
Main Authors: Friesen, Chance S., Chan, Sherwin S., Wagner, Jonathan B., Hosey‐Cojocari, Chelsea, Csanaky, Iván L., Shakhnovich, Valentina
Format: Article
Language:English
Subjects:
Acids
Adult
Adults
Age Factors
Bile
Biomarkers
Child
Children
Clinical Trials as Topic
Comorbidity
Disease Progression
End Stage Liver Disease - pathology
End Stage Liver Disease - prevention & control
Etiology
Fatty liver
FDA approval
Gastrointestinal surgery
Histopathology
Humans
Intervention
Lifestyles
Liver diseases
Liver transplantation
Non-alcoholic Fatty Liver Disease - drug therapy
Non-alcoholic Fatty Liver Disease - etiology
Non-alcoholic Fatty Liver Disease - pathology
Obesity
Patient Selection
Pediatric Obesity - complications
Pediatric Obesity - drug therapy
Pediatrics
Pharmacology
Ultrasonic imaging
Weight control
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Nonalcoholic fatty liver disease (NAFLD) affects up to 70% of children with obesity and has become the number one etiology for liver transplant in the United States. Early, effective intervention is critical to prevent disease progression into adulthood. Yet, it is seldom achieved through lifestyle modification alone. Thus, children must be included in NAFLD pharmacology trials, which, to date, continue to focus primarily on adult populations. This commentary serves as a call to action.
ISSN:1752-8054
1752-8062
DOI:10.1111/cts.12952